Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

mylan institutional llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use: the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of medroxyprogesterone acetate is contraindicated in the following conditions: medroxyprogesterone acetate should not be administered during pregnancy. [see contraindications and warnings and precautions (5.17) .] detectable amounts of drug have been identified in the milk of mothers receiving medroxyprogesterone acetate. [see warnings and precautions (5.13) .] medroxyprogesterone acetate is not indicated before menarche. use of medroxyprogesterone acetate is associated with significant loss of bmd. this loss of bmd is of particular concern during adolescence and early adulthood, a criti

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

cipla usa inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use: the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: -   known or suspected pregnancy or as a diagnostic test for pregnancy. -   active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . -   known or suspected malignancy of breast [see warnings and precautions (5.3)] . -   known hypersensitivity to medroxyprogesterone acetate injectable suspension (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . -   sign

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

amneal pharmaceuticals llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use: the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e. longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1) ] . the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to medroxyprogesterone acetate injectable suspension (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . - significant liv

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

mylan institutional llc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. the effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. there are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. limitation of use: while there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. it is not intended for use in women with multiple gestations or other risk factors for preterm birth. do not use hydroxyprogesterone caproate injection in women with any of the following conditions:   hydroxyprogesterone caproate is indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a his

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

lsne, inc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. the effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. there are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. limitation of use : while there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. it is not intended for use in women with multiple gestations or other risk factors for preterm birth. do not use hydroxyprogesterone caproate injection in women with any of the following conditions: - current or history of thrombosis or thromboembolic disorders - known or suspected breast cancer, other hormone-sens

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

remedyrepack inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate (mpa) injectable suspension, usp is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use : the use of mpa injectable suspension, usp is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of mpa injectable suspension, usp is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to mpa injectable suspension, usp (medro

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

prasco laboratories - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate (mpa) injectable suspension, usp is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use : the use of mpa injectable suspension, usp is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of mpa injectable suspension, usp is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to mpa injectable suspension, usp (medroxyprogesterone acetate or any of its other ingredients) [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.7)]

Kanada - engleski - Health Canada

pharmascience inc - progesterone - capsule - 100mg - progesterone 100mg - progestins

Kanada - engleski - Health Canada

pharmascience inc - progesterone - capsule - 200mg - progesterone 200mg - progestins

Kanada - engleski - Health Canada

pharmascience inc - medroxyprogesterone acetate - tablet - 2.5mg - medroxyprogesterone acetate 2.5mg - progestins